Clinical Research on Systemic Chemotherapy Combined With Bronchoscopic Seed Implantation in the Treatment of Advanced Lung Cancer

This study aims to explore the clinical value of systemic chemotherapy combined with bronchoscopic seed implantation in advanced lung cancer treatment. The study enrolled 253 patients with advanced lung cancer in Cangzhou People's Hospital from March 2018 to March 2020, and they were divided in...

Full description

Saved in:
Bibliographic Details
Published in:Technology in cancer research & treatment 2020-01, Vol.19, p.1533033820971600-1533033820971600
Main Authors: Xu, Feng, Yang, Jian, Xu, Beizheng, Li, Zhenzhen, Li, Xuanmei, Wu, Xiaotang, Liu, Haiyan
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor
Bronchoscopy - methods
Disease Management
Female
Humans
Iodine Radioisotopes - administration & dosage
Lung Neoplasms - diagnosis
Lung Neoplasms - etiology
Lung Neoplasms - mortality
Lung Neoplasms - therapy
Male
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Original
Tomography, X-Ray Computed
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aims to explore the clinical value of systemic chemotherapy combined with bronchoscopic seed implantation in advanced lung cancer treatment. The study enrolled 253 patients with advanced lung cancer in Cangzhou People's Hospital from March 2018 to March 2020, and they were divided into test group and control group. Test group was given systemic chemotherapy combined with bronchoscopic seed implantation, while control group was given systemic chemotherapy. The objective response rate of tumor (ORR), disease control rate (DCR), serum tumor marker level, survival time and adverse reactions of 2 groups were compared. After treatment, the levels of serum tumor markers including carcino-embryonic antigen, neuro-specific enolase, cytokeratin-19 and pro-gastrin-releasing peptide were markedly decreased in test group compared with those in control group ( < 0.05). Therein, the serum tumor marker level of non-small cell lung cancer (NSCLC) patients was significant decreased compared with that of small cell lung cancer (SCLC) patients in test group. Meanwhile, in test group, the serum tumor marker level of lung adenocarcinoma (LUAD) patients was significant decreased compared with that of lung squamous cell carcinoma (LUSC, < 0.05). The ORR and DCR in test group were superior to those in control group (63.4%, 92.5% 38.7%, 72.3%, < 0.05), while those were much higher in patients with NSCLC and LUAD relative to those in patients with SCLC and LUSC, respectively ( < 0.05). Furthermore, the progression-free survival (PFS) and overall survival (OS) in test group were significantly greater than those in control group. In test group, the PFS and OS of patients with NSCLC and LUAD were higher than those of patients with SCLC and LUSC. The efficacy of systemic chemotherapy combined with bronchoscopic seed implantation was superior to that of systemic chemotherapy, which is worthy of promoting in clinical practice.
ISSN:1533-0346
1533-0338
DOI:10.1177/1533033820971600